Inhibitory Potential of Cannabis Biomass Extracts on Livestock-Associated Staphylococcal and Streptococcal Pathogens

Overview

Journal Microorganisms

Specialty Microbiology

Date 2025 Feb 26

PMID 40005797

Authors

Tereza Paulova

Lucie Malikova

Davide Lanzoni

Tomas Taubner

Matej Malik

Marketa Houdkova

Eva Pechouckova

Affiliations

Soon will be listed here.

Abstract

Diseases caused by staphylococci and streptococci are a serious burden on livestock production, causing significant losses. In addition, the associated antibiotic resistance of these pathogens often makes treatment impossible or prolonged. L. contains many compounds with antibacterial properties and shows great potential as a natural antimicrobial agent for agricultural use against both of these bacterial species. The aim of this study was to compare the in vitro antibacterial activity of ethanol extracts from five cultivars of hemp, namely, Bialobrzeskie, Felina 32, Futura 75, mixed and Santhica 27, against , and . All five cultivars exhibited a certain degree of inhibitory effect against all the pathogens tested with minimum inhibitory concentrations (MICs) ranging from 128 to 2048 μg/mL. The extract from the Santhica 27 cultivar was the most effective antibacterial agent with the lowest MIC value of 128 μg/mL against and two clinical isolates of , followed by Bialobrzeskie and mixed cultivars with the same growth-inhibitory potential against . The extracts from the Felina 32 and Futura 75 cultivars presented only weak activity with MIC values ranging from 256 to 2048 μg/mL. The extract from the Santhica 27 cultivar appears to be a promising product for future use in the treatment of staphylococcal and streptococcal infections in livestock.

References

Skala T, Kahankova Z, Tauchen J, Janatova A, Kloucek P, Hubka V . Medical cannabis dimethyl ether, ethanol and butane extracts inhibit the growth of bacteria and dermatophytes causing common skin diseases. Front Microbiol. 2022; 13:953092. PMC: 9530109. DOI: 10.3389/fmicb.2022.953092. View

Lanzoni D, Skrivanova E, Pinotti L, Rebucci R, Baldi A, Giromini C . Review: Nutritional aspects of hemp-based products and their effects on health and performance of monogastric animals. Animal. 2024; 18(2):101058. DOI: 10.1016/j.animal.2023.101058. View

Taponen S, Liski E, Heikkila A, Pyorala S . Factors associated with intramammary infection in dairy cows caused by coagulase-negative staphylococci, Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, Corynebacterium bovis, or Escherichia coli. J Dairy Sci. 2017; 100(1):493-503. DOI: 10.3168/jds.2016-11465. View

Rondevaldova J, Hummelova J, Tauchen J, Kokoska L . In Vitro Antistaphylococcal Synergistic Effect of Isoflavone Metabolite Demethyltexasin with Amoxicillin and Oxacillin. Microb Drug Resist. 2017; 24(1):24-29. DOI: 10.1089/mdr.2017.0033. View

Vaou N, Stavropoulou E, Voidarou C, Tsigalou C, Bezirtzoglou E . Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives. Microorganisms. 2021; 9(10). PMC: 8541629. DOI: 10.3390/microorganisms9102041. View

Alves-Barroco C, Roma-Rodrigues C, Raposo L, Bras C, Diniz M, Caco J . Streptococcus dysgalactiae subsp. dysgalactiae isolated from milk of the bovine udder as emerging pathogens: In vitro and in vivo infection of human cells and zebrafish as biological models. Microbiologyopen. 2018; 8(1):e00623. PMC: 6341033. DOI: 10.1002/mbo3.623. View

Cheng W, Han S . Bovine mastitis: risk factors, therapeutic strategies, and alternative treatments - A review. Asian-Australas J Anim Sci. 2020; 33(11):1699-1713. PMC: 7649072. DOI: 10.5713/ajas.20.0156. View

Rao S, Linke L, Magnuson R, Jauch L, Hyatt D . Antimicrobial resistance and genetic diversity of collected from livestock, poultry and humans. One Health. 2022; 15:100407. PMC: 9582408. DOI: 10.1016/j.onehlt.2022.100407. View

Cos P, Vlietinck A, Vanden Berghe D, Maes L . Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. J Ethnopharmacol. 2006; 106(3):290-302. DOI: 10.1016/j.jep.2006.04.003. View

10.

van Klingeren B, ten Ham M . Antibacterial activity of delta9-tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek. 1976; 42(1-2):9-12. DOI: 10.1007/BF00399444. View

11.

Aqawi M, Sionov R, Gallily R, Friedman M, Steinberg D . Anti-Bacterial Properties of Cannabigerol Toward . Front Microbiol. 2021; 12:656471. PMC: 8100047. DOI: 10.3389/fmicb.2021.656471. View

12.

Blaskovich M, Kavanagh A, Elliott A, Zhang B, Ramu S, Amado M . The antimicrobial potential of cannabidiol. Commun Biol. 2021; 4(1):7. PMC: 7815910. DOI: 10.1038/s42003-020-01530-y. View

13.

Sionov R, Steinberg D . Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles. Biomedicines. 2022; 10(3). PMC: 8945038. DOI: 10.3390/biomedicines10030631. View

14.

Czauderna M, Taubner T, Wojtak W . Comparative Study of Gas and Liquid Chromatography Methods for the Determination of Underivatised Neutral and Acidic Cannabinoids and Cholesterol. Molecules. 2024; 29(10). PMC: 11124110. DOI: 10.3390/molecules29102165. View

15.

Bonini S, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M . Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018; 227:300-315. DOI: 10.1016/j.jep.2018.09.004. View

16.

Alfei S, Schito G, Schito A . Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. Pharmaceutics. 2023; 15(7). PMC: 10384972. DOI: 10.3390/pharmaceutics15071889. View